Maraviroc

ARV U.S. Brand Name

Selzentry

ARV Abbreviation(s)

MVC

U.S. FDA Label

Maraviroc Labeling (Package Insert)

ARV Class

Entry, fusion, and attachment inhibitors

First U.S. Approval

August 6, 2007

U.S. Manufacturer

ViiV Healthcare

Formulations

Strength	Formulation	Image	Description	Boosted
150 mg	Tablet	X	oval blue pill with 150 MVC	No
300 mg	Tablet	X	oval blue tablet with 300MVC imprinted	No

Generic Available?

Assistance Programs

ViiV Connect

Displaying 1 - 45 of 45

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Ritonavir MVC 1042	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Increased maraviroc effects		100 mg BID	Maraviroc AUC increased 161%; Cmin increased 355%; Cmax increased 28%	Reduce dose of maraviroc to 150 mg BID with strong CYP3A4 inhibitors
Darunavir MVC 884	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential for increased maraviroc adverse effects	Not reported	150 mg BID	Cmax increase 77%, AUC increase 210%, Cmin increase 427%	Use maraviroc 150 mg BID when combined with darunavir / ritonavir
Darunavir MVC 883	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential for increased maraviroc adverse effects	Not reported	150 mg BID	Cmax increase 129%, AUC increase 305%, Cmin increase 700%	Use maraviroc 150 mg BID when combined with darunavir / ritonavir
Atazanavir MVC 764	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential increase in maraviroc adverse effects	Not reported	300 mg BID	Maraviroc AUC increased 388%, Cmax increased 167%, Cmin increased 567%	Decrease maraviroc dose to 150 mg BID
Atazanavir MVC 763	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential increase in maraviroc adverse effects	Not reported	300 mg BID	Maraviroc AUC increased 257%, Cmax increased 109%, Cmin increased 319%	Decrease maraviroc dose to 150 mg BID
Nevirapine MVC 594	Green: Administer standard doses	Administer standard doses		Nevirapine AUC no significant change	300 mg single dose	Maraviroc Cmax increased 54%	Use standard dose maraviroc. If coadministering with nevirapine plus a protease inhibitor, reduce dose of maraviroc to 150 mg BID
Etravirine MVC 519	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc		No significant change	300 mg BID	Maraviroc AUC decreased 53%; Cmax decreased 60%; Cmin decreased 39%	Increase maraviroc to 600 mg BID when combined with etravirine. When etravirine and maraviroc are coadministered with a strong CYP3A4 inhibitor, decrease maraviroc dose to 150 mg BID
Etravirine MVC 518	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Increased maraviroc effects		150 mg BID	Maraviroc AUC increased 3.10 fold; Cmax increased 1.76 fold; Cmin increased 5.27 fold	Increase maraviroc to 600 mg BID when combined with etravirine. When etravirine and maraviroc are coadministered with a strong CYP3A4 inhibitor, decrease maraviroc dose to 150 mg BID
Etravirine MVC 517	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Increased maraviroc effects	No significant change on etravirine, darunavir or ritonavir pharmacokinetics	300 mg BID	Maraviroc AUC increased 210%; Cmax increased 77%; Cmin increased 430%	Increase maraviroc to 600 mg BID when combined with etravirine. When etravirine and maraviroc are coadministered with a strong CYP3A4 inhibitor, decrease maraviroc dose to 150 mg BID
Etravirine MVC 516	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Decreased maraviroc effects		300 mg BID	Maraviroc AUC decreased 53%; Cmax decreased 60%; Cmin decreased 39%	Increase maraviroc to 600 mg BID when combined with etravirine. When etravirine and maraviroc are coadministered with a strong CYP3A4 inhibitor, decrease maraviroc dose to 150 mg BID
Efavirenz MVC 364	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Decreased maraviroc effects		100 mg BID	Maraviroc AUC decreased 45%; Cmax decreased 51%; Cmin decreased 45%	Increase maraviroc dose to 600 mg BID
Efavirenz MVC 363	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of maraviroc	Decreased maraviroc effects		100 mg BID	Maraviroc AUC decreased 45%; Cmax decreased 51%; Cmin decreased 45%	Increase maraviroc dose to 600 mg BID
Raltegravir MVC 300	Green: Administer standard doses	Administer standard doses		Raltegravir AUC decreased 37%; Cmin decreased 28%; Cmax decreased 33%	300 mg Q12H	Maraviroc Cmin decreased 21%; Cmax decreased 20%
Maraviroc Oxcarbazepine 62	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decrease in antiretroviral efficacy				Use alternative agents
Maraviroc Eslicarbazepine 61	Orange: Minimal data to guide interaction	Minimal data to guide interaction: risks likely to outweigh benefits	Potential decrease in antiretroviral efficacy				Use alternative agents
Maraviroc St. John's Wort (Hypericum perforatum) 60	Red: Avoid combination	Do not coadminister: Potential for reduced levels of maraviroc	Potential decrease in antiretroviral efficacy				Use alternative agents
Maraviroc Dasabuvir + Ombitasvir / Paritaprevir / Ritonavir 59	Red: Avoid combination	Do not coadminister: Potential for increased levels of maraviroc	Potential maraviroc-associated adverse effects				Use alternative agents
Maraviroc RPT 58	Green: Administer standard doses	Do not coadminister: Potential for reduced levels of maraviroc	Potential decrease in antiretroviral efficacy				Use alternative agents
Maraviroc RAL 57	Green: Administer standard doses	Administer standard doses		Maraviroc AUC decreased 14%; Cmax decreased 21%	400 mg BID	Raltegravir AUC decreased 37%; Cmin decreased 27%
Maraviroc NVP 56	Green: Administer standard doses	Administer standard doses		Maraviroc AUC no change; Cmax increased 54%	200 mg BID	Not reported
Maraviroc RFB 55	Green: Administer standard doses	Administer standard doses		Maraviroc AUC no change; Cmin decreased 30%	300 mg daily	Not reported
Maraviroc Voriconazole 54	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects				Reduce maraviroc dose to 150 mg BID
Maraviroc Voriconazole 53	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects				Reduce maraviroc dose to 150 mg BID
Maraviroc Posaconazole 52	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects				Reduce maraviroc dose to 150 mg BID
Maraviroc Itraconazole 51	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects				Reduce maraviroc dose to 150 mg BID
Maraviroc Clarithromycin 50	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects				Reduce maraviroc dose to 150 mg BID
Maraviroc DRV 49	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc		Maraviroc Cmin increased 16%; Cmax no significant change (when compared to maraviroc 300 mg BID without darunavir / ritonavir in separate control arm)	800 / 100 mg BID	Not reported	Reduce dose of maraviroc to 150 mg BID
Maraviroc DRV/c 48	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc					Reduce dose of maraviroc to 150 mg BID
Maraviroc RTV 47	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects	Maraviroc AUC increased 161%; Cmax increased 28%	100 mg BID	Not reported	Reduce dose of maraviroc to 150 mg BID
Maraviroc DRV/r 46	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects	Maraviroc AUC increased 305%; Cmax increased 129%	600 mg / 100 mg BID	Not reported	Reduce dose of maraviroc to 150 mg BID
Maraviroc ATV/r 45	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects	Maraviroc AUC increased 388%; Cmax increased 167%	300 mg / 100 mg daily	Not reported	Reduce dose of maraviroc to 150 mg BID
Maraviroc ATV 44	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects	Maraviroc AUC increased 257%; Cmax increased 109%	400 mg daily	Not reported	Reduce dose of maraviroc to 150 mg BID
Maraviroc Elvitegravir / Cobicistat / Emtricitabine / Tenofovir alafenamide 43	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects				Reduce dose of maraviroc to 150 mg BID
Maraviroc ATV/c 42	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects				Reduce dose of maraviroc to 150 mg BID
Maraviroc Ketoconazole 41	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Increased maraviroc effects	Maraviroc AUC increased 400%; Cmax increased 238%; Cmin increased 275%	400 mg daily	Not reported	Reduce dose of maraviroc to 150 mg BID
Maraviroc Phenytoin 40	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Potential decrease in antiretroviral efficacy				Increase maraviroc dose to 600 mg BID. If including MVC, ETR plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
Maraviroc Phenobarbital 39	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Potential decrease in antiretroviral efficacy				Increase maraviroc dose to 600 mg BID. If including MVC, ETR plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
Maraviroc ETR 38	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Potential decrease in antiretroviral efficacy	Maraviroc AUC decreased 53%; Cmin decreased 39%	200 mg BID	Not reported	Increase maraviroc dose to 600 mg BID. If including MVC, ETR plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
Maraviroc CBZ 37	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Potential decrease in antiretroviral efficacy				Increase maraviroc dose to 600 mg BID. If including MVC, ETR plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
Maraviroc EFV 36	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc		Maraviroc AUC increased 15%; Cmax increased 16% when compared to maraviroc 100 mg BID given alone.	600 mg daily	Not reported	Increase maraviroc dose to 600 mg BID. If including MVC, EFV plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
Maraviroc EFV 35	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Potential decrease in antiretroviral efficacy	Maraviroc AUC decreased 45%; Cmax decreased 51%	600 mg daily	Not reported	Increase maraviroc dose to 600 mg BID. If including MVC, EFV plus a strong CYP3A4 inhibitor in the regimen, reduce maraviroc dose to 150 mg BID
Maraviroc RIF 34	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc		Maraviroc AUC increased 4%; Cmax decreased 3% when compared to maraviroc 100 mg BID given alone.	600 mg daily	Not reported	Increase maraviroc dose to 600 mg BID. If also including a strong CYP3A4 inhibitor in the regimen, consider using an alternative agent due to difficulty predicting maraviroc concentrations.
Maraviroc RIF 33	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of maraviroc	Potential decrease in antiretroviral efficacy	Maraviroc AUC decreased 63%; Cmax decreased 66%; Cmin decreased 78%	600 mg daily	Not reported	Increase maraviroc dose to 600 mg BID. If also including a strong CYP3A4 inhibitor in the regimen, consider using an alternative agent due to difficulty predicting maraviroc concentrations.
Fostemsavir MVC 13	Green: Administer standard doses	Administer standard doses		Temsavir Cmax increased 13%, AUC increased 10%, Cmin decreased 10%	300 mg BID	Maraviroc AUC increased 25%, Cmin increased 37%
Maraviroc

Subscribe to Maraviroc